Alzheimer’s Early Testing

Testing for Alzheimer’s disease early empowers preventive brain care to delay the onset of symptoms. Early detection leads to finding a cure for Alzheimer’s.

For the first time in history, our Alzheimer’s Early Detection Test enables doctors to diagnose Alzheimer’s disease decades before symptoms.


We track the prion biomarkers – abeta, tau, and synuclein – that drive Alzheimer’s.


Early detection is the missing key in the fight to end Alzheimer’s disease.

It’s Accurate. Private. Cost Efficient.

We are launching two types of services:

(Pending Regulatory Approvals)


C-PANEL is specifically for people who already show cognitive or motor symptoms suspected as being caused by Alzheimer’s, Parkinson’s or related neurodegenerative diseases. If clinical symptoms have already occurred, we recommend that your doctor contact us using this form for requirements in submitting CSF samples. This comprehensive test gives the most accurate and sensitive measurement of Prions in the brain, providing diagnostic analysis of the three (3) Prions: Abeta, Tau, and Synuclein.

Get C-Panel Test

This is EARLY DETECTION for people who do not show symptoms of neurodegenerative disease, but are at increased risk due to:

  • Brain Aging
  • Genetics
  • Repeated head injury
  • Family history
  • Other known or suspected risk factors

Your doctor may contact us using the form below to inquire about the requirements in submitting blood samples for our comprehensive testing of three (3) Prions: Abeta, Tau, and Synuclein. This test is less invasive, but it is also less sensitive and quantitative because the levels of Prions in the blood is 1% or less than that in the CSF. However, if Prions are present in the blood sample, our diagnostic will detect them.

Get B-Panel Test

What Is Alzheimer’s?

Alzheimer’s Disease is the leading cause of dementia. It appears to be linked to the presence of two misfolded proteins in the brain, called amyloid beta (image on the left) and tau. Here’s a picture of these misfolded proteins, also known as prions.

misfolded Abeta prion misfolded tau prions

Learn more about Alzheimer’s Disease here.

Although both proteins are present in normal brains, the misfolded proteins tend to form large clumps in the brains of most Alzheimer’s patients that are referred to as plaque and tangles.


Source: internet archive.

How is the brain affected by Alzheimer’s disease? The PET scan image below compares a normal brain with that a brain with mild cognitive impairment (MCI) and one that is affected by Alzheimer’s Disease.


Source: NIH.

Since dementia can also be caused by vascular disease and by other misfolded proteins, diagnosis of Alzheimer’s has been notoriously challenging.

The dementia and loss of memory in Alzheimer’s patients is due to progressive death of cells in the brain controlling memory and high-level thinking. Cell death appears to be caused by the presence of misfolded Abeta and Tau proteins.

These prions have the ability to spread from cell to cell throughout the brain, destroying the brain without detection for decades.
Watch this video Prion War to learn how misfolded proteins or prions destroy the brain in neurodegenerative diseases, such as Alzheimer’s.

There is currently no effective treatment to slow or stop the progression of Alzheimer’s disease.

Drugs targeting misfolded Abeta have not been successful in clinical trials.

Many experts believe that by the time Alzheimer’s symptoms have been detected, the disease is already irreversible. At this late stage, much of the brain has been destroyed.

To find a cure for Alzheimer’s Diseases, we will need to provide people with accurate and early testing decades before any symptoms start to appear. Early detection enables science to accelerate research in developing effective treatments to stop Alzheimer’s before we lose another generation.

Early Diagnosis of Alzheimer’s

When you or a family member experiences possible loss of memory, concentration or ability to speak and yet, you haven’t received a diagnosis, chances are you may be dealing with the early signs of Alzheimer’s. 

Waiting for a clear answer or a definitive diagnosis can be scary and frustrating, as there may be more questions than answers. Although currently there’s no cure yet, technological advances in biomarker testing will soon unlock the key to early diagnosis of Alzheimer’s.

With an early diagnosis, Alzheimer’s patients are able to confront and address the onset of symptoms of the disease before they fully develop, allowing patients to take proactive measures to keep the worst of the disease at bay. 

While certain drugs and other treatments may be able to reduce symptoms, environmental, behavioral and lifestyle changes can minimize the effect of the disease on the patient’s day-to-day life, as well as giving family more time to plan for the future.

As new treatments are developed, they are likely to give maximum benefit to patients diagnosed at the earliest stages of Alzheimer’s.

Early Signs of Alzheimer’s

For many, the early onset of Alzheimer’s starts with memory and concentration issues, such as forgetting important events and moments, as well as difficulty problem solving or planning. At home or at work, simple tasks may become more challenging, such as confusion of time and place. 

Driving may also become more challenging as spatial awareness declines, and items may be misplaced more frequently, leading to keys that always seem to be lost or a phone that’s never where you expect it to be. 

Language problems are also common, such as an inability to recall frequently-used words while speaking or writing. Poor judgment may cloud decision-making, and withdrawal from social engagements increases as symptoms make it more challenging to interact with others. 

Finally, mood and personality changes may occur as the disease takes hold and starts to affect more and more aspects of daily life.

Diagnosing Alzheimer’s Disease

With advances in bioscience, early diagnosis of Alzheimer’s is becoming more of a possibility with each passing day. It is currently up to your primary care doctor, a neurologist or a geriatrician to review your medical history and determine a diagnosis. 

Memory, as well as cognitive and behavioral tests can be conducted to see if a measurable decline might suggest Alzheimer’s. In addition,  tests such as brain imaging or regular blood work might help rule out other diseases that may be complicating an Alzheimer’s diagnosis. 

Depression, strokes, Parkinson’s disease and other medical conditions also mimic symptoms of Alzheimer’s, which can make diagnosis even more difficult.

To help assess the cognitive decline of a suspected Alzheimer’s patient, tests may include mental status tests that measure cognitive and memory skills, neurophysiological tests that measure performance during everyday tasks such as driving and bookkeeping, and interviews with friends and family to determine whether they’ve noticed any changes in behavior, memory or cognitive ability. 

It’s often the people around a patient who notice the first signs, though they may dismiss it as a simple mistake or due to normal brain aging.

The combination of all the information from the tests, friends and family interviews and the medical history may lead to a diagnosis of either no disease, minimal cognitive impairment or early Alzheimer’s. 

What is Minimal cognitive impairment? It is diagnosed when some cognitive loss is confirmed, but not enough for a diagnosis of Alzheimer’s. According to research, approximate 40% of patients with minimal cognitive impairment proceed to a diagnosis of Alzheimer’s within 10 years. Since most of the information obtained at this early stage is circumstantial and subjective, it would be extremely helpful to obtain a definitive testing based on biomarkers using blood or spinal fluid that clearly indicate the presence or absence of Alzheimer’s, as well as indiciation of the stages of the disease: early, intermediate, or late stages. 

Amprion and other companies are pioneering the development of diagnostic biomarkers that can indicate the presence of active Alzheimer’s disease both at early and late stages of disease. 

Amprion’s Early Detection of Alzheimer’s

Designed to diagnose and track the Prions, aka, misfolded proteins, that drive the progression of Alzheimer’s (and Parkinson’s), our biomarker-based tests let you and your doctor identify the causes of Alzheimer’s—the real culprit—not the symptoms.

Accurate, private and cost efficient, we’re launching two tests pending regulatory approval that use different biomarker detection signatures to determine an Alzheimer’s diagnosis. 

Our most sensitive and accurate testing for Alzheimer’s uses spinal fluid (CSF) to give the most accurate measurement of Prions in the brain, with a comprehensive analysis of signature biomarker Prions composed of misfolded Abeta, Tau and Synuclein. 

We are also developing the same tests using blood, intended for patients who suspect they may develop the disease due to aging, genetic factors, repeated head injuries, a family history or another type of suspected risk. 

To learn more about either of our tests, including how you may be able to join a trial or study, please have your doctor contact us.  Click here if you’re interested in taking an Alzheimer’s Quiz. To learn more about our Early Testing For Alzheimer’s, sign up for the Alzheimer’s Priority List

We believe our Alzheimer’s Early Testing℠ will accelerate drug development to stop Alzheimer’s disease. Join us in the fight to stop Alzheimer’s before we lose another generation.

Join Us To Fight Against Alzheimer’s Disease

Follow Amprion for breakthroughs and updates on testing availability.

    I'm a DoctorI'm a Neurologistother, please specify